Enhanced Recovery After Surgery (ERAS) are developed to provide a systematic structure for managing postsurgical patients.These protocols promote evidenced-based practices and implement a multidisciplinary effort to maintain normal physiology in the perioperative period and aid in earlier recovery. The present study aims to investigate the feasibility of and compliance to a structured ERAS protocol among Gynecological Oncological Centers in Greece as well as to compare the outcomes among patients that fullfilled the minimum number of necessary criteria, compared to those that were enrolled in ERAS protocols but did not meet the sufficient necessary criteria.
Enhanced Recovery After Surgery (ERAS) are developed to provide a systematic structure for managing postsurgical patients.These protocols promote evidenced-based practices and implement a multidisciplinary effort to maintain normal physiology in the perioperative period and aid in earlier recovery. ERAS protocols briefly include pre-admission education, pre-operative nutritional care, specific recommendations for pre-operative medications, a standardized anesthetic protocol, perioperative fluid management, multimodal analgesia (MMA), early mobilization, and early removal of urinary catheters. ERGO study study aims to investigate the feasibility of and compliance to a structured ERAS protocol among Gynecological Oncological Centers in Greece as well as to compare the outcomes among patients that fullfilled the minimum number of necessary criteria, compared to those that were enrolled in ERAS protocols but did not meet the sufficient necessary criteria. Patients will be registered into the trial before surgery. Quality assurance program will be in place for both patients that will fulfill the ERAS criteria as well as for those that will not fulfill them.
Study Type
OBSERVATIONAL
Enrollment
600
This group will include patients that achieved a compliance rate that exceeded 80% of the required predetermined criteria of ERAS protocols.
This group will include patients that do not follow the predetermined criteria of ERAS protocols
First department of Obstetrics and Gynecology
Athens, Athens, Greece
RECRUITINGAgios Savvas Anticancer Hospital
Athens, Attica, Greece
RECRUITINGFirst department of Obstetrics and Gynecology, National and Kapodistrian University of Athens
Athens, Attica, Greece
RECRUITINGUniversity of Thessaly
Larissa, Larissa, Greece
RECRUITINGMetaxa Anticancer Hospital
Athens, Piraeus, Greece
NOT_YET_RECRUITINGAristotle University of Thessaloniki, Second department of Obstetrics and Gynecology
Thessaloniki, Thessaloniki, Greece
RECRUITINGAristotle University of Thessaloniki, Third department of Obstetrics and Gynecology
Thessaloniki, Thessaloniki, Greece
RECRUITINGAristotle University of Thesalloniki, Papageorgiou Hospiral
Thessaloniki, Thessaloniki, Greece
RECRUITINGDuration of hospitalization
From date of hospitalization until the date of discharge or date of death from any cause, whichever came first, assessed up to 2 months.
Time frame: Up to 30 days postoperatively
Perioperative infections
Number of participants with postoperative infections (including surgical site, pulmonary and urinary tract infections)
Time frame: Postoperatively (30 days)
Postoperative quality of life
Documentation of quality of life using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C40) and the Functional Assessment of Cancer Therapy - General (FACT-G) questionnaires. The EORTC-QLQ C30 involves 30 questions that are rated from 1 (no impact on quality of life) to 4 (debilitating symptoms). The FACT-G assesses physical, family, emotional and functional wellbeing through 27 questions that are scaled from 0 (no impact) to 4 (very much).
Time frame: Postoperatively (30 days)
Postoperative morbidity (other than infectious) using the Clavien-Dindo classification
Major events such as pulmonary embolism,accuse myocardial infarction,etc
Time frame: 30 days
Interval to adjuvant therapy
The interval between surgical treatment and adjuvant therapy (radiation and/or chemotherapytreatment) will be documented
Time frame: Up to 100 days
Recurrence rates
Recurrent disease will be monitored through 3 year of follow up
Time frame: 3 years follow-up
Overall survival
Overall survival of the patients will be measured through 3 year of follow up
Time frame: 3 years follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.